ProShare Advisors
JANX icon

ProShare Advisors’s Janux Therapeutics JANX Stock Holding History

ProShare Advisors’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,495
Closed -$145K – 1954
2025
Q4 		$145K Buy
10,495
+1,621
+18% +$38.1K ﹤0.01% 1801
2025
Q3 		$217K Sell
8,874
-1,410
-14% -$34.3K ﹤0.01% 1654
2025
Q2 		$238K Buy
10,284
+771
+8% +$20.3K ﹤0.01% 1609
2025
Q1 		$257K Sell
9,513
-871
-8% -$32.8K ﹤0.01% 1515
2024
Q4 		$556K Buy
10,384
+2,003
+24% +$106K ﹤0.01% 1213
2024
Q3 		$381K Buy
8,381
+2,863
+52% +$125K ﹤0.01% 1307
2024
Q2 		$231K Sell
5,518
-1,137
-17% -$53.4K ﹤0.01% 1458
2024
Q1 		$251K Buy
+6,655
New +$145K ﹤0.01% 1536

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ProShare Advisors's JANX Position: Q1 2026 in Review

ProShare Advisors sold out of Janux Therapeutics (JANX) in Q1 2026, closing a stake of 10,495 shares — an estimated $145K sold.

ProShare Advisors first reported a position in JANX in Q1 2024 and held it in 8 quarters. The position peaked at $556K in Q4 2024. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

  • ProShare Advisors reported no remaining Janux Therapeutics position as of Q1 2026 after selling out during the quarter.
  • ProShare Advisors sold 10,495 Janux Therapeutics shares in Q1 2026, an estimated $145K.
  • ProShare Advisors first reported a position in Janux Therapeutics in Q1 2024 and held it in 8 quarters.
  • ProShare Advisors's Janux Therapeutics position peaked at $556K in Q4 2024.
  • 190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.